CN1846784A - Amphioxus PE glucoprotein and its production process - Google Patents
Amphioxus PE glucoprotein and its production process Download PDFInfo
- Publication number
- CN1846784A CN1846784A CNA2005101014587A CN200510101458A CN1846784A CN 1846784 A CN1846784 A CN 1846784A CN A2005101014587 A CNA2005101014587 A CN A2005101014587A CN 200510101458 A CN200510101458 A CN 200510101458A CN 1846784 A CN1846784 A CN 1846784A
- Authority
- CN
- China
- Prior art keywords
- limax
- glycoprotein
- pulmonary carcinoma
- powder
- slug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title description 4
- 241000251522 Cephalochordata Species 0.000 title 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 37
- 239000003814 drug Substances 0.000 claims abstract description 26
- 239000000843 powder Substances 0.000 claims abstract description 15
- 239000007924 injection Substances 0.000 claims abstract description 10
- 238000002347 injection Methods 0.000 claims abstract description 10
- 239000002775 capsule Substances 0.000 claims abstract description 7
- 239000008187 granular material Substances 0.000 claims abstract description 4
- 102000003886 Glycoproteins Human genes 0.000 claims abstract 4
- 108090000288 Glycoproteins Proteins 0.000 claims abstract 4
- 241001523405 Limax Species 0.000 claims description 18
- 239000006187 pill Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 238000005516 engineering process Methods 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000002547 new drug Substances 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 238000005185 salting out Methods 0.000 claims description 2
- 230000011218 segmentation Effects 0.000 claims description 2
- 235000019219 chocolate Nutrition 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 239000012567 medical material Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 235000004252 protein component Nutrition 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 238000011002 quantification Methods 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 abstract description 9
- 208000020816 lung neoplasm Diseases 0.000 abstract description 9
- 239000003826 tablet Substances 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 238000001959 radiotherapy Methods 0.000 abstract description 3
- 238000002512 chemotherapy Methods 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 241000237852 Mollusca Species 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 238000011160 research Methods 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 2
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 description 2
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 241000522620 Scorpio Species 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000009969 fructus bruceae Substances 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 239000008602 kang-lai-te Substances 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 239000009490 scorpio Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 1
- RAQNTCRNSXYLAH-RFCGZQMISA-N (20S)-ginsenoside Rh1 Chemical compound O([C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RAQNTCRNSXYLAH-RFCGZQMISA-N 0.000 description 1
- DPQCZNIGGNJGTD-UHFFFAOYSA-N Chloride-(??)-2-Methylpentanoic acid Natural products CCCCCCC=CCCCCCCCCCC(=O)OC(C)C(C)OC(=O)CCCCCCCC=CCCCCCC DPQCZNIGGNJGTD-UHFFFAOYSA-N 0.000 description 1
- DPQCZNIGGNJGTD-MVCBGFDASA-N Coixenolide Chemical compound CCCCCC\C=C\CCCCCCCCCC(=O)O[C@@H](C)[C@@H](C)OC(=O)CCCCCCC\C=C/CCCCCC DPQCZNIGGNJGTD-MVCBGFDASA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 1
- RAQNTCRNSXYLAH-UHFFFAOYSA-N Ginsenoside Rh1 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(C3)C)(C)C1C(O)CC2C1(C)CCC(O)C(C)(C)C1C3OC1OC(CO)C(O)C(O)C1O RAQNTCRNSXYLAH-UHFFFAOYSA-N 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to new lung cancer treating medicine. By means of biotechnology, slug PE4 glycoprotein as one kind of natural lung cancer treating medicine is extracted from slug as one crop harming mollusk. The extracted slug PE4 glycoprotein is further prepared into capsule, granule, tablet, injection or powder for injection. These slug PE4 glycoprotein preparations can kill lung cancer cell directly and effectively and reduce the main symptoms of lung cancer patient and has no acute toxic effect like that of chemotherapy and radiotherapy.
Description
[technical field]
The present invention relates to a kind of anti-pulmonary carcinoma new drug, particularly intend the natural drug-Limax PE of a kind of anti-pulmonary carcinoma that Applied Biotechnology extracts from Mollusca Limax Scorpio on one's body
4Glycoprotein, and made capsule preparations, granule, tablet, pill, drop pill, powder, syrup, aqueous injection, lyophilized injectable powder.
[background technology]
1, this malignant tumor of pulmonary carcinoma has become the No.1 killer who threatens human health
The sickness rate of pulmonary carcinoma is along with the aggravation of environmental pollution, and the speed with 11.90% since nearly 10 years rises.Global malignant tumor neopathy in 2000 has surpassed more than 1,000 ten thousand, dead 6,200,000 examples, and pulmonary carcinoma new cases 123.9 ten thousand examples wherein account for the cancer example 12.32% of always falling ill, and lung cancer death 110.3 ten thousand examples account for 17.77% of total death toll, all rank first.The whole world has 1,500,000-1,800,000 people to die from pulmonary carcinoma every year at present, and China's pulmonary carcinoma harm situation is even more serious, by per 100,000 people's 83.43 sickness rate calculating.The annual New Development lung cancer patient of China does not descend 1,000,000, dies from pulmonary carcinoma person every year and has reached 600,000 more than! Not following 3500 people of Shanghai City annual New Development pulmonary carcinoma case.This malignant tumor of pulmonary carcinoma has become the No.1 killer who threatens human health.Therefore, the special medicine of development effectively preventing pulmonary carcinoma has become the task of top priority of domestic and international the world of medicine, emphasis and focus.
2, the method for current treatment pulmonary carcinoma is a lot of with relevant medicine, but all has certain limitation
As treat the traditional method of pulmonary carcinoma excision, radiotherapy and chemotherapy (Drug therapy) are arranged.But be pulmonary carcinoma through clinical definite in a single day, 80% patient has just lost the chance of excision; And there be partial restricted and ray damaging to normal structure in radiotherapy; There is the restricted of universality cytotoxic effect and dosage thereof in chemistry (medicine) treatment; Serious to liver, kidney, bone marrow and digestive system toxic and side effects especially, restricted the therapeutic effect of pulmonary carcinoma greatly.Emerging interventional therapy has certain effect to primary tumor, but is difficult to tackle the metastasis of constantly distributing; Modern molecular targeted property (gene) treatment brings dawn to patients with lung cancer, but the interlinkage of its vector construction, carrier and bullet and the problems such as variation in body distribution, metabolic process thereof are also among discussion.
3, Chinese medicine is with a long history, but to the pulmonary carcinoma uncertain therapeutic efficacy, does not still have breakthrough
Because western medical treatment means, the particularly restriction of toxic and side effects that chemicotherapy had and subject range, Chinese medicine has occupied more and more important position in the treatment of pulmonary carcinoma.Along with the research institution of Chinese medicine and prevention and treatment in Chinese and western tumor is increasing, the new Chinese medicine of investing and developing or study treatment cancer or assistant treating cancer also increases year by year.Nearly more than 20 come the clinical and experimentation of anti-pulmonary carcinoma Chinese medicine to obtain remarkable progress, and this declares the treatment pulmonary carcinoma kind proof that also obtains in the majority from new Chinese medicine.According to the analysis of the anti-pulmonary carcinoma Chinese herbal medicine clauses and subclauses that " Chinese scientific and technological materials catalogue, Chinese herbal medicine " recorded since 1978, the research of anti-pulmonary carcinoma Chinese herbal medicine relates to monomer, single medicinal material extract, single medicinal material and compound recipe.Existing curative also has adjuvant.Dosage form comprises medicine for external use such as injection, oral agents and point-application.Peroral dosage form relates to a plurality of kinds such as electuary, powder, pill, unguentum, decoction, oral liquid.The existing clinical trial of research contents, animal experiment also have the drug mechanism research that is deep into cell and molecular level.On the whole, anti-pulmonary carcinoma Chinese herbal medicine is more deep to the research of monomer, single medicinal material extract, single medicinal material, and the mechanism of action is also relatively more thorough, and the research level of compound recipe remains further to be improved.Oral medicine research is more, and injection and medicine for external use research are less.The extract of the single medicinal material of being studied includes the Radix Paeoniae Rubra 801, ligustrazine, tanshinone, hirudin, Oleum Curcumae (elemene) of the effect of invigorating blood circulation etc.; Have the polyose medicament of setting upright antitumor action polyporusum bellatus, lentinan, lycium barbarum polysaccharide, coriolan, Dihuang polysaccharide etc. are arranged; Saponin class medicine have Radix Ginseng total saponins, Herb Gynostemmae Pentaphylli total glycosides, ginsenoside Rb1, Rg1, Re, Rh1, Rg3 and and Herba Epimedii glycoside etc.; Other medicines still comprise tetrandrine, tea pigment, coixenolide, beta-carotene, garlicin, two anhydrate diterpene-kind compound bF in melampyrin, the Herba Lobeliae Chinensis and Fructus Bruceae extract etc.Because it is more deep that the research of this type of medicine is done, mechanism research is also relatively more thorough, has therefrom obtained one one kind new medicine one ginseng capsule and some two kind new medicine injections, as elemene, KANGLAITE, Fructus Bruceae breast, cinobufacin etc.These injections not only can intravenously administrable, and all right tremulous pulse insertion administration that has has been opened up the new way of treatment by Chinese herbs pulmonary carcinoma administration.Whether although the Chinese medicine of existing treatment pulmonary carcinoma emerges in an endless stream, the existing single of dosage form has monomer and compound recipe again, yet comprises the modern Chinese medicine through the U.S. and Russia's participation clinical research as " KANGLAITE ZHUSHEYE ", definite to the pulmonary carcinoma curative effect, does not still have and generally acknowledges.Therefore, significant if can develop a kind of effective anti-pulmonary carcinoma new drug that has no side effect.
4, previous research work of the present invention is sturdy, and reliable experimental evidence is provided, and has represented bright market prospect
1. Limax dry powder leachate has the obvious suppression effect to the growth of the lung cell A549 that exsomatizes;
2. Limax dry powder leachate is to the double-deck agar clone cell of people's lung squamous cancer passage cell colony suppression ratio 93.08%, and is suitable with the matched group 93.33% of cisplatin; To human lung adenocarcinoma cell colony suppression ratio 65.24%, obviously be better than 34.77% of matched group cisplatin;
3. give the treatment of medium and advanced lung cancer volunteer with Limax Scorpio dry powder capsule: 3 groups of middle and advanced stage nonsmall-cell lung cancer 94 examples, short term effect: effective (CR+PR) 67.7% (57/94); Stablize 31.91% (30/94); Invalid 6.39% (6/94), and to the cough of lung cancer patient, cough up phlegm, symptom such as asthma and dyspnea has tangible mitigation, and can improve patient's quality of life significantly, do not find toxic and side effects;
4. use the segmentation salting out method in conjunction with lyophilization, extract, filter out Limax active ingredient-Limax PE
4Glycoprotein.And begun to take shape the technology path of suitability for industrialized production, for the following large-scale production capsule of this medicine, granule, tablet, pill, drop pill, powder, syrup, aqueous injection, lyophilized injectable powder lay the foundation.
5. use MTT colorimetry and soft agar cell culture clone forming method, positive control, repeated experiments, confirm the present invention (Limax PE
4Glycoprotein) lung adenocarcinoma cells A549 strain system and small cell lung cancer NCI-H446 cell strain system there is definite inhibitory action.
In a word: above-mentioned experimental research achievements of the present invention for realizing this program objective, provides certain scientific basis and research experience.
[summary of the invention]
Limax active ingredient-Limax PE
4Glycoprotein and production technology thereof.
[specific embodiments]
Limax adds in the distilled water-homogenate-centrifugal-get supernatant-with salt-adjustments degree of saturation-stand at low temperature spend the night-centrifugal-collection protein solution-dialysis removes salt ion-centrifugal-stay supernatant-vacuum lyophilization-must combine brown Limax PE
4Glycoprotein freeze dried powder-degerming is preserved.Then by the pharmacopeia standard, with Limax PE
4Glycoprotein is made capsule, tablet, pill, drop pill, powder, aqueous injection, lyophilized injectable powder respectively.
Claims (4)
1, a kind of anti-pulmonary carcinoma new drug that the present invention relates to is from bright Limax (or suddenly freezing fresh-keeping Limax) homogenate supernatant, the Limax PE that utilization segmentation salting out method extracts
4Glycoprotein (Slug PE
4Glycoprotein) protein quantification 6.4g/L, polyoses content 2.67g/L, the chocolate brown powder that forms through vacuum lyophilization.
2, the medical material that the present invention relates to is a Limax.The purpose medicine is Limax PE
4Glycoprotein, and made capsule: granule; Tablet; Pill, drop pill, powder, syrup, mixture, aqueous injection; Lyophilized injectable powder.
3, Limax PE
4The effect of glycoprotein is effectively to treat pulmonary carcinoma.
4, the processing technique that the present invention relates to is Limax homogenate, sucking filtration, the protein component of saltouing, and lyophilisation becomes the powder technology.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2005101014587A CN1846784A (en) | 2005-11-25 | 2005-11-25 | Amphioxus PE glucoprotein and its production process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2005101014587A CN1846784A (en) | 2005-11-25 | 2005-11-25 | Amphioxus PE glucoprotein and its production process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1846784A true CN1846784A (en) | 2006-10-18 |
Family
ID=37076665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005101014587A Pending CN1846784A (en) | 2005-11-25 | 2005-11-25 | Amphioxus PE glucoprotein and its production process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1846784A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008095429A1 (en) * | 2007-02-06 | 2008-08-14 | Guangzhou Konzern Pharmaceutical Co., Ltd. | A glycoprotein for treating chronic obstructive pulmonary diseases |
| EP2319873A4 (en) * | 2008-06-23 | 2011-06-22 | Guangzhou Konzern Pharmaceutical Co Ltd | Dextran for treating lung cancer |
| CN103610699A (en) * | 2013-12-06 | 2014-03-05 | 广州白云山汉方现代药业有限公司 | Extraction method of land slug and anti-lung cancer application of land slug |
| CN107865889A (en) * | 2016-09-27 | 2018-04-03 | 广西久福生物科技有限公司 | The new application of slug |
-
2005
- 2005-11-25 CN CNA2005101014587A patent/CN1846784A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008095429A1 (en) * | 2007-02-06 | 2008-08-14 | Guangzhou Konzern Pharmaceutical Co., Ltd. | A glycoprotein for treating chronic obstructive pulmonary diseases |
| JP2010517948A (en) * | 2007-02-06 | 2010-05-27 | グアンツォウ コンツェルン ファーマシューティカル カンパニー リミテッド | Glycoprotein for the treatment of chronic obstructive pulmonary disease |
| EP2319873A4 (en) * | 2008-06-23 | 2011-06-22 | Guangzhou Konzern Pharmaceutical Co Ltd | Dextran for treating lung cancer |
| JP2011525550A (en) * | 2008-06-23 | 2011-09-22 | 広州康采恩医薬有限公司 | Dextran for lung cancer treatment |
| CN103610699A (en) * | 2013-12-06 | 2014-03-05 | 广州白云山汉方现代药业有限公司 | Extraction method of land slug and anti-lung cancer application of land slug |
| CN107865889A (en) * | 2016-09-27 | 2018-04-03 | 广西久福生物科技有限公司 | The new application of slug |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113908229B (en) | Traditional Chinese medicine preparation for eliminating pulmonary nodules and preparation and application thereof | |
| CN103070880B (en) | Application of acanthopanax trifoliatus polysaccharide in preparing medicine for treating diabetes | |
| CN104491740B (en) | A kind of Chinese medicine composition for treating liver cancer and preparation method thereof | |
| CN1939346A (en) | Slug polysaccharide and its making method | |
| CN118434431A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN102895515A (en) | Chinese medicinal composition for raising leucocytes and preparation method and application thereof | |
| CN108434399A (en) | A kind of Chinese medicine composition and preparation method of anti-curing oncoma | |
| CN1846784A (en) | Amphioxus PE glucoprotein and its production process | |
| CN1173726C (en) | Medicine for curing malignant turnor and its preparation method | |
| CN102940808A (en) | Prescription medicine for treating lung cancer and preparation method | |
| CN104056242A (en) | Traditional Chinese medicine composition for treating acute cholecystitis and preparation method thereof | |
| CN114177261A (en) | Chinese herbal medicine formula for preventing and treating chronic diseases and resisting cancer and protecting health | |
| CN100411663C (en) | Compound traditional Chinese medicine anti-cancer powder and preparation method thereof | |
| CN1394646A (en) | Anticancer Chinese medicine powder preparation and its preparation method | |
| CN116115714B (en) | Anti-tumor Chinese medicine composition and its preparation method and application | |
| CN105617319A (en) | Preparation method of traditional Chinese medicine composition for treating acute cholecystitis | |
| CN103816392B (en) | Pharmaceutical composition of a kind for the treatment of organs fibrosis and its production and use | |
| CN103191268B (en) | Traditional Chinese medicinal composition for treating lung cancer | |
| CN107441151A (en) | A kind of Chinese medicine preparation for treating breast cancer and preparation method thereof | |
| Jin et al. | Progress of experimental researches on Chinese herbal compounds for inducing tumor cell apoptosis | |
| CN1824156A (en) | Chinese medicine mixed preparation for treating stomach precancer and its preparation method | |
| CN102293857A (en) | Invention of effective component in glutinous rehmannia and plantain prescription for treating chronic glomerulonephritis | |
| CN120189453A (en) | Traditional Chinese medicine composition of radix ginseng rubra and preparation method thereof | |
| CN105055933B (en) | One kind is used for treating cancer Chinese medicine composition and preparation method thereof, preparation and application | |
| CN119424562A (en) | A Chinese medicine composition, preparation and application for treating drug-induced renal injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |